Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Mark Alles Biography and Net Worth

CEO of Bristol-Myers Squibb

Mark J. Alles serves as Independent Director of the Company. Mr. Alles served as chairman and chief executive officer of Celgene Corporation, a global biopharmaceutical company, from March 2016 until its acquisition by Bristol-Myers Squibb Company in November 2019. Prior to this role, Mr. Alles served as Celgene’s president and chief operating officer from August 2014 to February 2016 and as its chief commercial officer and executive vice president, hematology & oncology from December 2012 to July 2014. Mr. Alles joined Celgene in April 2004. Before joining Celgene, he served in senior commercial management roles at Aventis Pharmaceuticals Inc. (Rhône-Poulenc Rorer) from 1993 to 2004. Mr. Alles received B.S. degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps.

What is Mark J. Alles' net worth?: The estimated net worth of Mark J. Alles is at least $641,977.35 as of October 31st, 2022. Mr. Alles owns 10,905 shares of Bristol-Myers Squibb stock worth more than $641,977 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Alles may own. Learn More about Mark J. Alles' net worth.
How do I contact Mark J. Alles?: The corporate mailing address for Mr. Alles and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Mark J. Alles' contact information.
Has Mark J. Alles been buying or selling shares of Bristol-Myers Squibb?: Mark J. Alles has not been actively trading shares of Bristol-Myers Squibb over the course of the past ninety days. Most recently, on Wednesday, May 9th, Mark J. Alles bought 1,208 shares of Bristol-Myers Squibb stock. The stock was acquired at an average cost of $82.60 per share, with a total value of $99,780.80. Following the completion of the transaction, the chief executive officer now directly owns 187,316 shares of the company's stock, valued at $15,472,301.60. Learn More on Mark J. Alles' trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 6,901 shares worth more than $349,655.16. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Mark J. Alles Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/9/2018	Buy	1,208	$82.60	$99,780.80	187,316
2/8/2018	Buy	3,260	$91.90	$299,594.00	178,904
2/6/2015	Sell	117,099	$120.68	$14,131,507.32

Mark J. Alles Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $58.87

$57.62

$58.92

50 Day Range

MA: $53.66

$49.02

$59.82

2 Week Range

Now: $58.87

$39.35

$61.08

Volume

7,412,808 shs

Average Volume

12,398,418 shs

Market Capitalization

$119.40 billion

P/E Ratio

N/A

Dividend Yield

4.12%

Beta

0.44

Trump won. Buy this coin now.

From Weiss Ratings | Ad